Bottom line
Between 2022 and early 2025, compounding pharmacies legally produced semaglutide and tirzepatide under 503A and 503B exemptions while the FDA-declared drug shortage was active. That shortage has been officially resolved for both molecules — semaglutide in February 2025 and tirzepatide in October 2024.
This changes the legal landscape substantially:
- Compounding pharmacies can no longer produce semaglutide or
tirzepatide under the standard shortage exemption.
- Some compounding continues under narrow clinical exceptions
(documented allergy to an excipient in the brand product, specific dose form not commercially available).
- The FDA has sent warning letters to compounding pharmacies that
continued producing after the shortage ended.
- Patients currently on compounded GLP-1s need to transition to
brand-name products or alternative therapies.
Compounded semaglutide and tirzepatide are not FDA-approved. The FDA has not reviewed them for safety, efficacy, potency, sterility, or quality. This has always been the case, even during the shortage.
How compounding exemptions work
Federal law allows two categories of compounding pharmacies:
503A pharmacies compound medications based on individual patient prescriptions. They are state-regulated and must hold state pharmacy board licenses. During a declared shortage, they can compound copies of commercially available drugs.
503B outsourcing facilities are FDA-registered and can produce compounded drugs in larger quantities without patient- specific prescriptions. They are subject to FDA inspection and current good manufacturing practice (cGMP) requirements, though at a lower standard than full pharmaceutical manufacturers.
The critical distinction: both 503A and 503B compounding of a commercially available drug is permitted only during an FDA-declared shortage of that drug. When the shortage is resolved, the exemption expires.
The current legal status (April 2026)
Semaglutide: shortage officially resolved by the FDA in February 2025. Compounding under the shortage exemption is no longer authorized. Some 503B facilities have challenged this in court; as of mid-2026, the legal landscape is still in flux for specific facilities, but the FDA's position is clear: routine compounding of semaglutide is not authorized.
Tirzepatide: shortage officially resolved in October 2024. Same legal framework applies. Compounding under the shortage exemption is not authorized.
Exceptions that may still apply:
- A prescriber documents that a specific patient has a medically
necessary reason for a compounded formulation (e.g., documented allergy to an inactive ingredient in the brand product).
- A dose form not commercially available is needed (e.g., a
specific concentration for a patient who cannot use the commercially available pen or vial).
These exceptions are narrow and require genuine clinical documentation. "Patient prefers compounded because it's cheaper" is not a valid exception.
What happened to quality during the shortage
During the shortage period, the FDA issued multiple warnings about compounded GLP-1 products:
- Potency variability. FDA testing of compounded semaglutide
products found instances of sub-potent and super-potent formulations — meaning patients received either less drug than intended or more.
- Sterility concerns. Injectable compounded products must be
sterile. FDA inspections of 503B facilities found sterility failures in some cases.
- Salt form confusion. Some compounding pharmacies dispensed
"semaglutide sodium" or "semaglutide acetate" rather than the base semaglutide molecule. The clinical equivalence of these salt forms to the brand product has not been established. Patients and prescribers sometimes assumed they were interchangeable when they may not be.
- Adverse event reports. The FDA received adverse event
reports associated with compounded GLP-1 products, including reports of reactions potentially related to sterility or potency issues rather than the drug itself.
None of this means every compounded GLP-1 product was dangerous. Many 503B facilities maintained high standards. But the variability was real, and patients had no reliable way to distinguish high-quality from low-quality compounders without doing substantial due diligence.
If you're currently on a compounded GLP-1
Your prescriber should be actively transitioning you. The standard approaches:
1. Transition to brand-name product. If you were on compounded semaglutide, the transition is to Wegovy (for weight management) or Ozempic (for type 2 diabetes). If compounded tirzepatide, the transition is to Zepbound or Mounjaro. Dose translation is approximate — work with your prescriber to find the equivalent branded dose.
2. Use manufacturer direct programs for cash pricing. LillyDirect offers Zepbound at $349-549/month. NovoCare offers Wegovy at $499-649/month. These are meaningfully cheaper than pharmacy cash prices and were created partly in response to the compounding market.
3. Pursue insurance coverage. If you haven't already tried insurance, this is the time. The brand products may be covered, especially for diabetes (Mounjaro, Ozempic) or cardiovascular risk reduction (Wegovy with the SELECT indication). See our insurance coverage guide.
4. Consider oral options. The Wegovy pill and orforglipron are both oral GLP-1 options approved in 2026. If your primary barrier was injection aversion and compounded products offered a lower-commitment entry point, oral brand-name options may be a better fit.
The pricing reality
The compounded GLP-1 market existed largely because brand-name pricing was prohibitive for many patients. Compounded semaglutide during the shortage era ran $150-350/month — roughly a third of the brand-name cash price.
In 2026, the pricing landscape has shifted:
- Brand cash prices remain high (~$1,000-1,100/month at list)
- Manufacturer direct programs (LillyDirect, NovoCare) offer
$349-649/month for self-pay
- Insurance coverage has expanded — roughly 40-45% of large
employer plans now cover at least one GLP-1 for obesity
- Compounded pricing (for facilities still operating under
claimed exceptions) remains $150-350/month
The gap between compounded and brand has narrowed but is still significant for patients who don't have insurance coverage. This is the core tension — and it's the reason some compounding facilities are fighting the FDA's position in court.
Risks of continuing compounded GLP-1s
If you're considering staying on a compounded product after the shortage has been resolved:
- Legal risk to the pharmacy. If the FDA determines the
compounding is unauthorized, the pharmacy faces enforcement action. Your supply could be interrupted without warning.
- Quality risk. Without the shortage exemption as a legal
shield, facilities under FDA scrutiny may cut corners or rush operations.
- No adverse event infrastructure. Brand manufacturers
maintain pharmacovigilance systems. Compounders generally do not.
- Prescriber risk. Your prescriber may face scrutiny for
continuing to prescribe compounded products without valid clinical justification.
What to ask your prescriber
- "Is my compounding pharmacy still legally authorized to
produce this drug?"
- "What's the transition plan to brand-name product?"
- "Can we get insurance coverage for the brand version?"
- "Would LillyDirect or NovoCare pricing work for me?"
- "Are there oral options that might fit my budget and
preferences?"
What this means for you
The compounded GLP-1 era was a response to genuine access problems — branded drugs were expensive and in short supply, and compounding pharmacies filled the gap for millions of patients. That era is largely over. The legal framework has shifted, and staying on compounded products carries risks that didn't exist during the shortage.
If cost is the primary barrier to brand-name therapy, the manufacturer direct programs and expanding insurance coverage have meaningfully closed the gap. The compounded product was never FDA-approved and was always a compromise — a reasonable one during a shortage, but one that no longer has the same legal or clinical justification.
Work with your prescriber on the transition. Don't wait for a supply interruption to force it.